Novartis brings Lutathera to adolescents with rare cancer in first for radioligand class
Novartis’ Lutathera is now the first radiopharmaceutical approved for adolescents with a rare cancer found in the gut.
The radioligand therapy won a
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
